Annexon(NASDAQ) ANNX

Annexon, Inc. makes medicines for rare nerve and eye diseases. These treatments stop the body from damaging its own healthy cells. The company helps patients who have few or no other options.

The Therapeutic Pipeline

• Tanruprubart: Target-specific protein treatment designed to treat Guillain-Barré Syndrome, which is a rare emergency where the immune system attacks the nerves.
• Vonaprument: Eye-injected medicine aimed at protecting vision in patients with geographic atrophy, a condition that causes blindness.
• ANX1502: Oral tablet under study for autoimmune conditions such as cold agglutinin disease.

Moving Toward Commercial Approval

• Filed a Marketing Authorization Application with the European Medicines Agency for tanruprubart in Jan. 2026.
• Entered a sales agreement in March 2026 to potentially sell up to $150.0 million in common stock.
• Expanded the Phase 3 ARCHER II trial for vonaprument in 2026 to include a two-year primary endpoint.
• Selected by the European Medicines Agency for a pilot program in July 2025 to help speed up regulatory interactions.

Stopping Inflammation at the Source

The company focuses on blocking C1q, a specific protein that starts a process called the classical complement pathway. By stopping this process, Annexon aims to prevent the immune system from damaging vital tissues in the brain and eyes.

Key Financial Facts

• Net loss was $55.3 million for the three-month period ended June 30, 2026, up 13% year over year.
• Research and development expenses reached $82.4 million for the six-month period ended June 30, 2026, down 11% year over year.
• Cash, cash equivalents, and short-term investments totaled $209.2 million as of June 30, 2026.
• The company reported an accumulated deficit of approximately $1.0 billion as of June 30, 2026.
• General and administrative expenses rose 41% to $10.6 million for the three months ended June 30, 2026.

Bottom Line

Annexon has transitioned from early research to late-stage clinical testing of therapies aimed at stopping neuroinflammation. The company is currently focused on securing its first regulatory approvals and preparing for potential commercial launches.